Intech Investment Management LLC Has $740,000 Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Intech Investment Management LLC reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 47.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,639 shares of the specialty pharmaceutical company's stock after selling 5,880 shares during the quarter. Intech Investment Management LLC's holdings in Jazz Pharmaceuticals were worth $740,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock valued at $264,750,000 after purchasing an additional 99,705 shares during the period. Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock worth $194,346,000 after acquiring an additional 527,187 shares during the period. Baupost Group LLC MA raised its position in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock worth $136,000,000 after acquiring an additional 440,552 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company's stock valued at $130,447,000 after acquiring an additional 398,549 shares during the last quarter. Finally, Swedbank AB acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at about $106,936,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Down 0.9 %

JAZZ traded down $1.05 on Friday, reaching $121.59. 286,839 shares of the company traded hands, compared to its average volume of 675,459. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a market cap of $7.35 billion, a price-to-earnings ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock's 50 day moving average price is $114.87 and its 200-day moving average price is $111.12.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. Corporate insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

JAZZ has been the topic of a number of research reports. Needham & Company LLC reiterated a "buy" rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research report on Monday, November 18th. Piper Sandler restated an "overweight" rating and issued a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Finally, Royal Bank of Canada upped their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $175.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.